Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.
Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.
Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.
More Innate Pharma news
Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million
INNATE PHARMA initiates collaboration with Celgene
Innate Pharma reports positive phase IIa in type C viral hepatitis
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights
Venture&Growth
Proverum
Proverum is an Irish medical device company founded in 2016 as a spin-off from Trinity College Dublin, developing novel treatment solutions for patients with symptomatic benign prostatic hyperplasia (BPH). BPH is a highly prevalent condition impacting an estimated 14 million
Venture&Growth
Purespring Therapeutics
Founded in 2020, Purespring is a pioneering London (UK)-based gene therapy company focused on transforming treatments for patients suffering from chronic kidney diseases. It is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell
Venture&Growth
Shoulder Innovations
Shoulder Innovations is a US-based medical device company that is commercializing a novel shoulder arthroplasty portfolio paired with an AI-enabled surgical planning software. The portfolio is anchored by Shoulder Innovations’ proprietary InSetTM glenoid fixing technology to solve the problem of